Introductie
Methode
Onderzoeksopzet
Populatie
Analyses
Resultaten
Overleving na ORC versus RARC
karakteristieken | ORC | RARC | p-waarde | ontbrekende data, % (n) |
---|---|---|---|---|
n = 1.086 | n = 386 | |||
leeftijd, jaren | 69 (62–75) | 68 (62–74) | 0,07a | 0 (1) |
geslacht % (n) | 0,09b | 0 | ||
vrouw | 27 (298) | 24 (92) | ||
man | 73 (788) | 76 (294) | ||
Charlson Comorbidity Index | 4 (2–5) | 4 (2–5) | 0,81a | 1 (20) |
ASA-classificatie, % (n) | 0,31b | 6 (81) | ||
– I | 17 (172) | 18 (70) | ||
– II | 62 (620) | 64 (245) | ||
– III–IV | 21 (216) | 18 (68) | ||
body mass index, kg/m2 | 26 (23–28) | 26 (23–29) | 0,13a | 9 (137) |
hemoglobine, mmol/l | 8,2 (7,1–9,0) | 8,2 (7,3–8,9) | 0,87a | 2 (26) |
creatinine, μmol/l | 90 (75–108) | 85 (73–104) | 0,01a | 3 (38) |
klinisch T‑stadium % (n) | 0,07b | 2 (29) | ||
– cTa/T1/cis | 19 (204) | 22 (83) | ||
– cT2 | 49 (529) | 52 (200) | ||
– cT3 | 24 (259) | 19 (74) | ||
– cT4 | 7 (75) | 5 (19) | ||
klinisch N‑stadium % (n) | < 0,01b | 2 (35) | ||
– cN0 | 91 (968) | 97 (362) | ||
– cN1 | 9 (94) | 4 (13) | ||
urinedeviatie, % (n) | 0,19b | 0 (6) | ||
– Bricker | 86 (928) | 82 (313) | ||
– neoblaas | 12 (126) | 14 (53) | ||
– Indiana pouch | 2 (21) | 3 (11) | ||
– ureterocutaneostomie | 1 (5) | 1 (4) | ||
– anders | 1 (5) | 0 | ||
jaar van operatie, % (n) | 0,01b | 0 | ||
– 2012 | 24 (261) | 18 (68) | ||
– 2013 | 26 (287) | 22 (83) | ||
– 2014 | 25 (275) | 30 (117) | ||
– 2015 | 24 (263) | 31 (118) | ||
neoadjuvante therapie, % (n) | 0,08b | 1 (10) | ||
– geen | 78 (843) | 73 (277) | ||
– chemotherapie | 21 (222) | 26 (99) | ||
– radiotherapie | 1 (10) | 0 (1) | ||
– anders | 1 (8) | 1 (2) |
overleving | |||
---|---|---|---|
HR | 95%-BI | p-waarde | |
leeftijd per jaar | 1,02 | 1,01–1,03 | < 0,01 |
vrouwelijk geslacht | 1,15 | 0,97–1,36 | 0,11 |
Charlson Comorbidity Index | |||
– < 5 | referentie | ||
– 5 | 1,22 | 0,97–1,53 | 0,11 |
– > 5 | 1,51 | 1,22–1,87 | < 0,01 |
ASA-classificatie | |||
– I | referentie | ||
– II | 0,94 | 0,75–1,17 | 0,57 |
– III–IV | 0,99 | 0,75–1,32 | 0,99 |
body mass index per kg/m2 | 0,99 | 0,96–1,01 | 0,16 |
anemiea | 1,37 | 1,15–1,63 | < 0,01 |
creatinine per 10 μmol/l | 1,01 | 0,99–1,02 | 0,35 |
klinisch T‑stadiumb | |||
– cTa/T1/cis | referentie | ||
– cT2-cT4 | 1,24 | 0,98–1,58 | 0,07 |
klinisch N‑stadium N + | 1,26 | 0,94–1,69c | 0,13 |
jaar van operatie | |||
– 2012 | 0,9 | 0,72–1,13 | 0,36 |
– 2013 | 1,02 | 0,82–1,27 | 0,83 |
– 2014 | 1,02 | 0,82–1,28 | 0,83 |
– 2015 | referentie | ||
neoadjuvante therapieb | |||
– geen | referentie | ||
– chemotherapie/radiotherapie | 0,85 | 0,68–1,07 | 0,16 |
ernstige complicatiesd | |||
– geen | referentie | ||
– ≥ 1 | 1,76 | 1,50–2,07 | < 0,01 |
pathologisch T‑stadiumb | |||
– pT0-pT2 | referentie | ||
– pT3-pT4 | 2,36 | 14,98–2,80 | < 0,01 |
pathologisch N‑stadium N+ | 1,82 | 1,53–2,17 | < 0,01 |
status positieve snijvlakken | 1,69 | 1,37–2,09 | < 0,01 |
ORC | 1 | 0,84–1,20 | 0,96 |
NAC en overleving
alle patiënten (n = 965) | alleen RC (n = 739) | NAC + RC (n = 226) | p-waarde | |
---|---|---|---|---|
leeftijd, jaren | 68 (62–74) | 69 (63–75) | 65 (59–71) | < 0,01 |
Geslacht, n (%) | ||||
– man | 704 (73) | 540 (73) | 164 (73) | 0,88 |
– vrouw | 261 (27) | 199 (27) | 62 (27) | |
creatinine, μmol/l | 89 (75–106) | 88 (74–103) | 96 (78–112) | < 0,01 |
klinisch T‑stadium; n (%) | ||||
– cT2 | 657 (68) | 561 (76) | 96 (43) | < 0,01 |
– cT3-4a | 264 (27) | 153 (21) | 111 (49) | |
– cT4a | 44 (5) | 25 (3) | 19 (8) | |
Charlson Comorbidity Index; n (%) | ||||
– 0–4 | 670 (70) | 486 (66) | 184 (81) | < 0,01 |
– 5–6 | 205 (21) | 170 (23) | 35 (16) | |
– > 6 | 80 (8) | 74 (10) | 6 (3) | |
– Missing | 10 (1) | 9 (1) | 1 (< 1) | |
NAC-regime; n (%) | ||||
– gem/cis | – | – | 162 (71) | – |
– gem/carbo | – | – | 35 (16) | |
– MVAC | – | – | 29 (13) | |
pathologische respons; n (%) | ||||
– complete respons (pCR) | 161 (17) | 91 (12) | 70 (31) | < 0,01 |
– partiële respons (pPR) | 87 (9) | 57 (8) | 30 (13) | |
– resterende ziekte (RZ) | 717 (74) | 591 (80) | 125 (56) |